A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)-- ranibizumab (Lucentis)-- maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.
---
Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, David S. Boyer, Peter K. Kaiser, Carol Y. Chung, and Robert Y. Kim. "Ranibizumab for Neovascular Age-Related Macular Degeneration". NEJM. Vol. 355, No. 14, pp. 1419-31. [ Permalink ] |